Esoteric Testing Global Market Report 2024

The esoteric testing market size has grown rapidly in recent years. It will grow from $29.24 billion in 2023 to $32.73 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historical period can be attributed to progress in biotechnology, an increase in chronic diseases, the evolution of precision medicine, a heightened focus on rare diseases, and discoveries in genomics.

The esoteric testing market size is expected to see rapid growth in the next few years. It will grow to $51.62 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. The anticipated growth in the forecast period can be attributed to the demand for early disease detection, the increasing geriatric population, the growth of precision oncology, the expansion of rare disease research, and global health challenges. Major trends in the forecast period include liquid biopsies and circulating biomarkers, microbiome analysis, integration of AI and machine learning, point-of-care esoteric testing, and expanded genetic and molecular testing.

The growth of the esoteric testing market is anticipated to be driven by the increasing prevalence of infectious diseases. Infectious diseases, caused by pathogens such as bacteria and viruses, are on the rise due to factors such as migration, travel, and environmental changes. Esoteric testing, which employs advanced technologies such as nucleic acid technology for detecting the genetic material of infectious agents, offers more accurate and sensitive results compared to traditional methods such as microbiological culture. For instance, according to the World Health Organization in March 2023, there were 247 million reported cases of malaria in 2021, indicating an increase of 2 million compared to the 245 million cases reported in 2020. Therefore, the growing prevalence of infectious diseases is a key driver for the esoteric testing market.

The growth of the esoteric testing market is expected to be fueled by the increasing geriatric population. The geriatric population, comprising individuals aged 65 years and older, has specific health and social needs. As this demographic continues to expand, the esoteric testing market becomes pivotal in advancing healthcare diagnostics and personalized medicine, contributing to better medical management and overall well-being for the elderly. For instance, a report by The Administration for Community Living (ACL) in May 2021 highlighted a 36% increase in the population aged 65 and older, rising from 39.6 million in 2009 to 54.1 million in 2019. Projections suggest that this demographic will reach 94.7 million by 2060, with those aged 80 and older surpassing 80.8 million by 2040. This represents more than double the figures from 2000 and constitutes 21.6% of the total population, compared to 16% in 2019. Therefore, the growing geriatric population is a significant driver for the esoteric testing market.


The esoteric testing market is witnessing a significant trend in technological advancements. Major companies in this market are actively developing innovative products based on advanced technologies to maintain their competitive positions. For example, in January 2021, OPKO Health Company, a US-based diagnostics and pharmaceuticals firm, introduced the Scarlet Health digital platform. This platform, designed for in-home, mobile, and flexible on-demand diagnostic services, capitalizes on the national presence and infrastructure of Bio-Reference, a US-based medical laboratory company.

Companies in the esoteric testing market are particularly focused on product launches, such as automated chemiluminescent enzyme immunoassay analyzers, to improve assay analytical specifications, enhance user-friendliness, and boost analytical performance. An automated chemiluminescent enzyme immunoassay analyzer is an advanced laboratory instrument utilizing chemiluminescent reactions and enzyme immunoassay techniques for automated and highly sensitive biomolecule detection. For instance, in May 2023, Tosoh Bioscience - Diagnostics EMEA, a Japan-based company, introduced the AIA-CL300, a new compact automated chemiluminescent enzyme immunoassay analyzer. This launch emphasizes enhanced sensitivity, improved workflow automation, versatility for laboratories of varying sizes, predictable consumption, calibration stability, and user-friendly features to prevent errors. These attributes collectively address the specific needs of the esoteric testing market, ensuring precise and reliable detection of low abundance biomarkers while streamlining processes and maintaining consistent performance for accurate and reproducible results.

In September 2021, Labcorp, a US-based medical diagnostics company, acquired Myriad Genetics' autoimmune disease unit for an undisclosed amount. This strategic acquisition positioned Labcorp to offer comprehensive diagnostic solutions for various diseases, including rheumatoid arthritis. Myriad Genetics is a US-based genomic testing company specializing in esoteric testing.

Major companies operating in the esoteric testing market report are LabCorp Holdings, Quest Diagnostics Inc., Eurofins Scientific SE, Sonic Healthcare Limited, Miraca Holdings Inc., H.U. Group Holdings Inc., Arup Laboratories Inc., OPKO Health Inc., Mayo Medical Laboratories, SYNLAB International GmbH, Myriad Genetics Inc., Bio-Reference Laboratories Inc., NeoGenomics Laboratories, Foundation Medicine Inc., Health Network Laboratories, Fulgent Genetics Inc., Grifols S.A., Adaptive Biotechnologies Corporation, Genova Diagnostics, Kind star Globalgene Technology Inc., National Medical Services Inc. (NMS), ACM Global Laboratories LLC, Miraca Life Sciences Inc., Leo Labs Inc., Pacific Bio labs Inc., Lab21 Healthcare Ltd., HealthQuest Esoterics Inc., Georgia Esoteric And Molecular Laboratory LLC., Atherotech Diagnostics Lab, Spectra Laboratories Inc.

North America was the largest region in the esoteric testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esoteric testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the esoteric testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The types of esoteric testing include infectious diseases testing, endocrinology testing, oncology testing, genetics testing, toxicology testing, immunology testing, neurology testing, and others. These tests utilize various technologies such as chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA (deoxyribonucleic acid) sequencing, flow cytometry, and others. Esoteric testing is conducted by independent and reference laboratories, as well as hospital-based laboratories.

The esoteric testing market research report is one of a series of new reports that provides esoteric testing market statistics, including the esoteric testing industry's global market size, regional shares, competitors with esoteric testing market share, detailed esoteric testing market segments, market trends and opportunities, and any further data you may need to thrive in the esoteric testing industry. This esoteric testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The esoteric testing market consists of revenues earned by entities by providing biochemical genetic tests, cytogenetic tests, and special coagulation tests, along with sample collection and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The esoteric testing market also includes the sales of immunoassays, DNA (deoxyribonucleic acid) sequencing kits, immunoassays, chromatography systems, mass spectrometers, and PCR (polymerase chain reaction) kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.